Akci\u011fer kanseri, d\u00fcnya genelinde kansere ba\u011fl\u0131 \u00f6l\u00fcmlerin en yayg\u0131n nedeni olarak ilk s\u0131ralarda kendini g\u00f6steriyor. En b\u00fcy\u00fck sorun ise hastal\u0131\u011f\u0131n genellikle belirti vermeden ilerlemesi. Ancak geli\u015fen teknolojiyle birlikte d\u00fc\u015f\u00fck doz bilgisayarl\u0131 tomografi (LDCT) taramalar\u0131, hastal\u0131\u011f\u0131 erken evrede yakalama imk\u00e2n\u0131 vadediyor. S\u00f6z konusu tarama y\u00f6ntemi hakk\u0131nda bilgi veren Medicana Sa\u011fl\u0131k Grubu G\u00f6\u011f\u00fcs Hastal\u0131klar\u0131 B\u00f6l\u00fcm\u00fc\u2019nden Do\u00e7. Dr. Nuran Katg\u0131, bilimsel \u00e7al\u0131\u015fmalar\u0131n, bu y\u00f6ntemle akci\u011fer kanserine ba\u011fl\u0131 \u00f6l\u00fcmlerin y\u00fczde 20\u2019ye varan oranlarda azalt\u0131labilece\u011fini g\u00f6sterdi\u011fini s\u00f6yledi. Do\u00e7. Dr. Nuran Katg\u0131, “Belirti beklemeden tarama yapt\u0131r\u0131n, erken tan\u0131 hayat kurtar\u0131r” dedi.
\n
D\u00fcnyada en s\u0131k g\u00f6r\u00fclen kanser t\u00fcrlerinden biri olan akci\u011fer kanserine y\u00f6nelik Medicana International \u0130zmir Hastanesi G\u00f6\u011f\u00fcs Hastal\u0131klar\u0131 Uzman\u0131 Do\u00e7. Dr. Nuran Katg\u0131, \u00f6nemli a\u00e7\u0131klamalarda bulundu. Do\u00e7. Dr. Nuran Katg\u0131, akci\u011fer kanserinin sessiz ilerleyen bir hastal\u0131k oldu\u011funa dikkat \u00e7ekerek, d\u00fc\u015f\u00fck doz bilgisayarl\u0131 tomografi (BT) ile akci\u011fer kanserinin erken te\u015fhis edilebilece\u011fini anlatt\u0131. Do\u00e7. Dr. Nuran Katg\u0131, “Akci\u011fer kanseri, d\u00fcnya genelinde kansere ba\u011fl\u0131 \u00f6l\u00fcmlerin en ba\u015f\u0131nda yer almaktad\u0131r. Bunun ba\u015fl\u0131ca nedeni, hastal\u0131\u011f\u0131n genellikle belirti vermeden ilerlemesidir. Semptomlar ortaya \u00e7\u0131kt\u0131\u011f\u0131nda hastal\u0131k \u00e7o\u011funlukla ileri evreye ula\u015fm\u0131\u015ft\u0131r. Sigara en \u00f6nemli risk fakt\u00f6r\u00fcd\u00fcr; buna ek olarak hava kirlili\u011fi, asbest, radon, genetik yatk\u0131nl\u0131k ve mesleki fakt\u00f6rler de etkili olur. Ge\u00e7 tan\u0131 konmas\u0131, tedavi \u015fans\u0131n\u0131 d\u00fc\u015f\u00fcr\u00fcr ve mortaliteyi y\u00fcksek tutar” a\u00e7\u0131klamas\u0131n\u0131 yapt\u0131. Erken te\u015fhisin \u00f6nemine de vurgu yapan Do\u00e7. Dr. Nuran Katg\u0131, “Erken evrede tan\u0131 konan hastalarda cerrahi tedaviyle tam k\u00fcr elde edilebilir. Erken tan\u0131, hastal\u0131\u011f\u0131n di\u011fer organlara yay\u0131lmadan yakalanmas\u0131n\u0131 sa\u011flar. Bu durum sa\u011fkal\u0131m\u0131 belirgin \u015fekilde art\u0131r\u0131r. Gecikmi\u015f vakalarda ise tedavi se\u00e7enekleri s\u0131n\u0131rl\u0131d\u0131r” dedi.<\/p>\n
Erken evre t\u00fcm\u00f6rler LDCT ile yakalanabilir
\n
D\u00fc\u015f\u00fck doz bilgisayarl\u0131 tomografinin (LDCT), akci\u011ferlerin d\u00fc\u015f\u00fck radyasyon dozu kullan\u0131larak g\u00f6r\u00fcnt\u00fclendi\u011fi \u00f6zel bir tarama y\u00f6ntemi oldu\u011funu aktaran Do\u00e7. Dr. Nuran Katg\u0131, “Klasik toraks BT\u2019de ortalama radyasyon dozu 6-7 mSv iken, LDCT\u2019de 1-2 mSv civar\u0131ndad\u0131r. Yani, 3-5 kat daha d\u00fc\u015f\u00fck radyasyonla y\u00fcksek \u00e7\u00f6z\u00fcn\u00fcrl\u00fckl\u00fc g\u00f6r\u00fcnt\u00fcler elde edilir” dedi. Do\u00e7. Dr. Nuran Katg\u0131, “Bilimsel veriler g\u00fc\u00e7l\u00fcd\u00fcr. ABD\u2019de yap\u0131lan NLST (National Lung Screening Trial) \u00e7al\u0131\u015fmas\u0131, d\u00fc\u015f\u00fck doz BT taramas\u0131n\u0131n akci\u011fer kanserine ba\u011fl\u0131 \u00f6l\u00fcmleri y\u00fczde 20 oran\u0131nda azaltt\u0131\u011f\u0131n\u0131 g\u00f6stermi\u015ftir. Avrupa\u2019da yap\u0131lan NELSON \u00e7al\u0131\u015fmas\u0131 da benzer \u015fekilde mortalitede belirgin azalma saptam\u0131\u015ft\u0131r. Bu sonu\u00e7lar, erken evre t\u00fcm\u00f6rlerin LDCT ile yakalanabilece\u011fini g\u00f6stermektedir” ifadelerini kaydetti.<\/p>\n
50-80 ya\u015f aras\u0131 herkes LDCT ile tarama yapt\u0131rmal\u0131
\n
Uluslararas\u0131 k\u0131lavuzlara g\u00f6re 50-80 ya\u015f aras\u0131, en az 20 paket-y\u0131l sigara \u00f6yk\u00fcs\u00fc olan ve h\u00e2len i\u00e7en veya son 15 y\u0131l i\u00e7inde b\u0131rakm\u0131\u015f bireylerin y\u0131lda bir kez LDCT taramas\u0131 yapt\u0131rmas\u0131n\u0131n faydal\u0131 olabilece\u011fini s\u00f6yleyen Do\u00e7. Dr. Nuran Katg\u0131, “Tarama genellikle y\u0131lda bir kez yap\u0131l\u0131r. \u015e\u00fcpheli bulgu saptan\u0131rsa, 3-6 ay gibi k\u0131sa aral\u0131klarla kontrol \u00e7ekimi \u00f6nerilir. Rutin tarama sigara i\u00e7meyenler i\u00e7in \u00f6nerilmez. Ancak pasif i\u00e7icilik, aile \u00f6yk\u00fcs\u00fc, radon veya asbest maruziyeti gibi ek risk fakt\u00f6rleri varsa hekim de\u011ferlendirmesi gerekir. LDCT\u2019nin radyasyon dozu, klasik BT\u2019ye g\u00f6re \u00e7ok daha d\u00fc\u015f\u00fckt\u00fcr (yakla\u015f\u0131k 1-2 mSv). Bu oran do\u011fal \u00e7evresel radyasyona yak\u0131nd\u0131r, dolay\u0131s\u0131yla hastalar g\u00fcvenle yapt\u0131rabilir. LDCT i\u015flemi a\u011fr\u0131s\u0131z, k\u0131sa s\u00fcrede tamamlanan, kontrast madde kullan\u0131lmayan bir y\u00f6ntemdir. Risk minimaldir; esas \u00f6nemli olan, sonu\u00e7lar\u0131n do\u011fru yorumlanmas\u0131 ve gereksiz tetkiklerden ka\u00e7\u0131n\u0131lmas\u0131d\u0131r. Her tarama testinde oldu\u011fu gibi LDCT\u2019de de yanl\u0131\u015f pozitif sonu\u00e7lar olabilir. Ancak Lung-RADS sistemiyle bu oranlar y\u00fczde 10-13 seviyelerine d\u00fc\u015fm\u00fc\u015ft\u00fcr. Yanl\u0131\u015f negatif oranlar\u0131 ise d\u00fc\u015f\u00fckt\u00fcr; d\u00fczenli y\u0131ll\u0131k tarama bu riski daha da azalt\u0131r” diye konu\u015ftu.<\/p>\n
Belirti beklemeden tarama yapt\u0131r\u0131n
\n
Akci\u011fer kanserinin bir numaral\u0131 nedenlerinden biri de sigara kullan\u0131m\u0131 oldu\u011funu hat\u0131rlatan Do\u00e7. Dr. Nuran Katg\u0131, “Akci\u011fer kanserine kar\u015f\u0131 sigara b\u0131rakmak en \u00f6nemli ad\u0131md\u0131r ancak risk tamamen ortadan kalkmaz. 50-80 ya\u015f aral\u0131\u011f\u0131nda 20 paket-y\u0131l sigara \u00f6yk\u00fcs\u00fc olan herkes y\u0131lda bir kez LDCT taramas\u0131 yapt\u0131rmal\u0131d\u0131r. Erken tan\u0131 hayat kurtar\u0131r. Akci\u011fer kanseri genellikle belirti vermeden ilerler. \u015eikayetler ba\u015flad\u0131\u011f\u0131nda hastal\u0131k \u00e7o\u011fu zaman ge\u00e7 evrededir. Belirti beklemeden tarama yapt\u0131rmak, hastal\u0131\u011f\u0131 erken evrede yakalaman\u0131n en etkili yoludur. Y\u00fcksek risk grubunda yap\u0131lan d\u00fczenli LDCT taramalar\u0131, \u00f6l\u00fcmleri anlaml\u0131 \u00f6l\u00e7\u00fcde azaltmaktad\u0131r. Erken tan\u0131 konan her hasta, kazan\u0131lm\u0131\u015f bir hayatt\u0131r. Erken tan\u0131, g\u00fc\u00e7l\u00fc hasta-hekim ileti\u015fimiyle m\u00fcmk\u00fcnd\u00fcr. Hastalar d\u00fczenli taramaya kat\u0131ld\u0131k\u00e7a, hekimler de sonu\u00e7lar\u0131 do\u011fru y\u00f6netti\u011finde ba\u015far\u0131 oran\u0131 artar. Multidisipliner yakla\u015f\u0131m, erken tan\u0131n\u0131n ba\u015far\u0131s\u0131nda kilit rol oynar” mesaj\u0131n\u0131 verdi.
<\/p>\n","protected":false},"excerpt":{"rendered":"
Akci\u011fer kanseri, d\u00fcnya genelinde kansere ba\u011fl\u0131 \u00f6l\u00fcmlerin en yayg\u0131n nedeni olarak ilk s\u0131ralarda kendini g\u00f6steriyor. En b\u00fcy\u00fck sorun ise hastal\u0131\u011f\u0131n genellikle belirti vermeden ilerlemesi. Ancak geli\u015fen teknolojiyle birlikte d\u00fc\u015f\u00fck doz bilgisayarl\u0131 tomografi (LDCT) taramalar\u0131, hastal\u0131\u011f\u0131 erken evrede yakalama imk\u00e2n\u0131 vadediyor. S\u00f6z konusu tarama y\u00f6ntemi hakk\u0131nda bilgi veren Medicana Sa\u011fl\u0131k Grubu G\u00f6\u011f\u00fcs Hastal\u0131klar\u0131 B\u00f6l\u00fcm\u00fc\u2019nden Do\u00e7. Dr….<\/p>\n","protected":false},"author":1,"featured_media":68862,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_crdt_document":"","footnotes":""},"categories":[2],"tags":[],"class_list":["post-68861","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik"],"_links":{"self":[{"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/posts\/68861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68861"}],"version-history":[{"count":1,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/posts\/68861\/revisions"}],"predecessor-version":[{"id":68863,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/posts\/68861\/revisions\/68863"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/media\/68862"}],"wp:attachment":[{"href":"https:\/\/www.egemtv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}